Functional redundancy of the nuclear factor κB inhibitors IκBα and IκBβ

Journal of Experimental Medicine

Volumn 188, Issue 6, 1998, Pages 1055-1062

  Cheng, Janet D ^a   Ryseck, Rolf Peter ^a   Attar, Ricardo M ^a   Dambach, Donna ^a   Bravo, Rodrigo ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hematopoiesis; I B; Nuclear factor B; Transgenic mice knockout mice

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL MODEL; ARTICLE; EVOLUTION; HEMATOPOIESIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THYMOCYTE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; DNA-BINDING PROTEINS; EMBRYO; FEMALE; FIBROBLASTS; GENETIC VECTORS; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B; RECOMBINATION, GENETIC; SEQUENCE DELETION; SIGNAL TRANSDUCTION; THYMUS GLAND;

EID: 0032555927     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.6.1055     Document Type: Article

References (37)

1. Gilmore, T.D. 1997. Introduction: the Rel/NF-κB signal transduction pathway. Cancer Biol. 8:61-62.
2. Whiteside, S.T., and S. Israël. 1997. IκB proteins: structure, function and regulation. Cancer Biol. 8:75-82.
3. Israel, A. 1995. A role for phosphorylation and degradation in the control of NF-κB activity. Trends Genet. 11:203-205.
4. Beg, A.A., and A.S. Baldwin, Jr. 1993. The IκB proteins: multifunctional regulators of Rel/NF-κB transcription factors. Genes Dev. 7:2064-2070.
5. Beg, A.A., W.C. Sha, R.T. Bronson, and D. Baltimore. 1995. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9:2736-2746.
6. Klement, J.F., N.R. Rice, B.D. Car, S.J. Abbondanzo, G.D. Powers, H. Bhatt, C.-H. Chen, C.A. Rosen, and C.L. Stewart. 1996. IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 16:2341-2349.
7. Ishikawa, H., D. Carrasco, E. Claudio, R.-P. Ryseck, and R. Bravo. 1997. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J. Exp. Med. 186:999-1014.
8. Franzoso, G., L. Carlson, T. Scharton-Kersten, E.W. Shores, S. Epstein, A. Grinberg, T. Tran, E. Shacter, A. Leonardi, M. Anver, et al. 1997. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture and germinal center reactions. Immunity. 6:479-490.
9. Schwarz, E.M., P. Krimpenfort, A. Berns, and I.M. Verma. 1997. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 11:187-197.
10. Zabel, U., and P.A. Baeuerle. 1990. Purified human IκB can rapidly dissociate the complex of the NF-κB transcription factor with its cognate DNA. Cell. 61:255-265.
11. Thompson, J.E., R.J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh. 1995. IκB-β regulates the persistent response in a biphasic activation of NF-βB. Cell. 80:573-582.
12. Chu, Z.-L., T.A. Mckinsey, L. Liu, X. Qi, and D.W. Ballard. 1996. Basal phosphorylation of the PEST domain in IκBβ regulates its functional interaction with the c-rel proto-oncogene product. Mol. Cell. Biol. 16:5974-5984.
13. Tybulewicz, V.L.J., C.E. Crawford, P.K. Jackson, R.T. Bronson, and R.C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1153-1163.
14. Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober. 1992. Isolation and fractionation of mononuclear cell populations. In Current Protocols in Immunology. J.W. Sons, editor. Greene Publishing Associates & Wiley-Interscience, New York. 3.0.1-3.0.5.
15. Schreiber, E., P. Matthias, M.M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucl. Acids Res. 17:6419.
16. Ishikawa, H., R.-P. Ryseck, and R. Bravo. 1996. Characterization of ES cells deficient for the p105 precursor (NF-κB1): role of p50 NLS. Oncogene. 13:255-263.
17. Dobrzanski, P., R.-P. Ryseck, and R. Bravo. 1993. Both N-and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif. Mol. Cell. Biol. 13:1572-1582.
18. Beg, A.A., W.C. Sha, R.T. Bronson, S. Ghosh, and D. Baltimore. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature. 376: 167-169.
19. de Martin, R., B. Vanhove, Q. Cheng, E. Hofer, V. Csizmadia, H. Winkler, and F.H. Bach. 1993. Cytokine-inducible expression in endothelial cells of an IκBα-like gene is regulated by NFκB. EMBO (Eur. Mol. Biol. Organ.) J. 12:2773-2779.
20. Le Bail, O., R. Schmidt-Ullrich, and A. Israel. 1993. Promoter analysis of the gene encoding the IκB-α/MAD3 inhibitor of NF-κB: positive regulation by members of the rel/ NF-κB family. EMBO (Eur. Mol. Biol. Organ.) J. 12:5043-5049.
21. Miyamoto, S., B.J. Seufzer, and S.D. Shumway. 1998. Novel IκBα proteolytic pathway in WEHI231 immature B cells. Mol. Cell. Biol. 18:19-29.
22. Attar, R.M., H. Macdonald-Bravo, C. Raventos-Suarez, S.K. Durham, and R. Bravo. 1998. Expression of constitutively active IκBβ in T cells of transgenic mice: persistent NF-κB activity is required for T-cell immune responses. Mol. Cell. Biol. 18:477-487.
23. Suyang, H., R. Phillips, I. Douglas, and S. Ghosh. 1996. Role of unphosphorylated, newly synthesized IκBβ in persistent activation of NF-κB. Mol. Cell. Biol. 16:5444-5449.
24. Kalli, K., C. Huntoon, M. Bell, and D.J. McKean. 1998. Mechanism responsible for T-cell antigen receptor-and CD28-or interleukin 1 (IL-1) receptor-mediated regulation of IL-2 gene expression by NF-κB. Mol. Cell. Biol. 18:3140-3148.
25. Whiteside, S.T., J.-C. Epinat, N.R. Rice, and A. Israël. 1997. IκB∈, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO (Eur. Mol. Biol. Organ.) J. 16:1413-1426.
26. Li, Z., and G.J. Nabel. 1997. A new member of the IκB protein family. IκB∈, inhibits RelA (p65)-mediated NF-κB transcription. Mol. Cell. Biol. 17:6184-6190.
27. Attar, R.M., J. Caamano, D. Carrasco, V. Iotsova, H. Ishikawa, R.-P. Ryseck, F. Weih, and R. Bravo. 1997. Genetic approaches to study Rel/NF-κB/IκB function in mice. Semin. Cancer Biol. 8:93-101.
28. Iotsova, V., J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo. 1997. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3:1285-1289.
29. Ishikawa, H., E. Claudio, D. Dambach, C. Raventos-Suarez, C. Ryan, and R. Bravo. 1998. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-κB1) but expressing p50. J. Exp. Med. 187:985-996.
30. Carrasco, D., J. Cheng, A. Lewin, G. Warr, H. Yang, C. Rizzo, F. Rosas, C. Snapper, and R. Bravo. 1998. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 187:973-984.
31. Caamano, J.H., C.A. Rizzo, S.K. Durham, D.S. Barton, C. Raventos-Suarez, C.M. Snapper, and R. Bravo. 1998. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarthitecture and B cell-mediated immune responses. J. Exp. Med. 187:185-196.
32. Franzoso, G., L. Carlson, L. Poljak, E.W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Scharton-Kersten, M. Anver, P. Love, K. Brown, and U. Siebenlist. 1998. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med. 187:147-159.
33. Weih, F., D. Carrasco, S.K. Durham, D.S. Barton, C.A. Rizzo, R.-P. Ryseck, S.A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/ Rel family. Cell. 80:331-340.
34. Sha, W.C., H.-C. Liou, E.I. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell. 80:321-330.
35. Kontgen, F., R.J. Frumont, A. Strasser, D. Metcalf, R. Li, D. Targlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9:1965-1977.
36. Hanks, M., W. Wurst, L. Anson-Cartwright, A.B. Auerbach, and A.L. Joyner. 1995. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science. 269:679-682.
37. Wang, Y., P.N.J. Schnegelsberg, J. Dausman, and R. Jaenisch. 1996. Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin. Nature. 379:823-825.